Report of the Trustees and Financial Statements for the Year Ended 31 March 2025 

> Patron: His Majesty King Charles III | Vice President: His Royal Highness The Duke of Gloucester Registered Charity Number 213251 (England and Wales) SC039715 (Scotland) Registered company number 324748 

1 



## **Lepra (limited by guarantee)** 

## **CHAIR AND CHIEF EXECUTIVE’S REPORT** 

2024-2025 was a milestone year for Lepra, as we celebrated our Centenary, launched our new Global Strategy, and had the tremendous honour to be selected for Royal Patronage by His Majesty King Charles III. 

These landmarks were built on our long and rich history of working with and for people affected by leprosy and lymphatic filariasis (LF) and give us guidance and direction for the future ahead. 

The Centenary celebrations were marked in style with various events held throughout the year, including: a reception at the Houses of Parliament, a mass at Westminster Cathedral, a BBC Radio 4 charity appeal, the publication of a History of Lepra by Irene Allen (who worked for Lepra for 38 years), and a Royal Tea Party at St. James Palace, hosted by our Vice President, His Royal Highness The Duke of Gloucester. 

Our new six-year Global Strategy for 2024-2030 was launched in April 2024 with a new Vision of ‘a world free from leprosy and lymphatic filariasis (LF)’; and an updated Mission to ‘work in partnership with people affected by leprosy and LF to improve detection, ensure access to treatment and care, and promote inclusion and wellbeing’. 

The strategy is a comprehensive and ambitious plan, which is going to challenge us in the coming years, requiring us to think differently, introduce some new ways of working, and focus us on improving our quality and efficiency. 

In December 2024, the Blue Peter Health and Research Centre in Hyderabad turned 25 years old, in which time it has implemented 50 national and international research projects, published 120 scientific publications, treated more than 5,000 people, and carried out 20,000 lab tests. We will build on its work and success in the years ahead. 

In 2024 we initiated a global advocacy campaign to develop better dosing guidance for multi drug therapy (MDT) for children under-10 who have been diagnosed with leprosy. To date, there is no appropriate drug formulation for young children. As a result of our advocacy, global players like the World Health Organization (WHO) have committed to ensure that this gap is addressed. 

The Mind2Heart project in Bangladesh continued to provide excellent community-led mental health and wellbeing support to more than 300 people affected by leprosy in Bogura District. The Aspire project in Bihar, India had excellent results in its Active Case Finding (ACF) approach, where every single village in Jamui District was screened, reaching 86% of all households, and finding three times the usual number of leprosy and LF cases being diagnosed. This is an impressive and important achievement. 

In the midst of all of these highlights we remain acutely aware of how much more needs to be done for people affected by leprosy and LF. Leprosy still exists. LF still exists. Millions of people live with the lifelong impacts of both. We will continue to do all we can to serve their needs. 



Suzanne McCarthy Chair of the Trustees 

Jimmy Innes Chief Executive 

2 



## **Lepra (limited by guarantee)** 

## **REPORT OF THE TRUSTEES AND STRATEGIC REPORT** 

**The Trustees submit their report and the audited financial statements for the year ended 31 March 2025.** 

The consolidated financial statements have been prepared under the accounting policies set out in Note 2 of the financial statements. These have been prepared in accordance with the Memorandum and Articles of Association and the Charities Statement of Recommended Practice 2019 (FRS102). 

For the purposes of the Companies Act 2006, the Board of Trustees is the Board of Directors of the charitable company and is referred to as the “Trustees” throughout this report. As required by the constitution, the Trustees are also members of the organisation. The Trustees and Officers of Lepra during the period and to the date of signing this report are as follows: 

## **Trustees** 

Mrs S McCarthy (Chair) 

Mrs S Bhasin 

Ms K Bigmore (resigned 3[rd] December 2024) 

Prof. R Hay 

Mr N Raynaud 

Mr S Singh (appointed 8[th] October 2024) 

Mr N Solanki (appointed 8[th] October 2024) 

Mr L Thomas 

Dr S Walker 

Mrs K Crabtree 

## **Officers** 

Chief Executive Officer: 

Mr J Innes 

Company Secretary: 

Mr N Avery (resigned 10th May 2024) 

Miss V Kuyela (appointed 10[th] May 2024) 

## **Bankers** 

Barclays Bank UK PLC, 9 High Street, Colchester, Essex, CO1 1DD 

Metrobank PLC, 31-32 High Street, Colchester, Essex, CO1 1DB 

## **Auditors:** 

Crowe U.K.LLP, 4th Floor, St James House, St James Place, Cheltenham, GL50 3PR 

## **Principal Office:** 

28 Middleborough, Colchester, CO1 1TG 

3 



Our Trustee Board is responsible and accountable for Lepra by setting the strategy and ensuring good governance, legal, and ethical compliance. This year, the Trustees have especially focused on governance and the new six-year Global Strategy (2024–2030), income generation, and safeguarding. 

The work of the Board of Trustees is supported by three standing Sub-Committees; 

## **Audit Finance and Risk Sub-Committee** 

Mrs S Bhasin (Chair) 

Mrs S McCarthy 

Mr N Raynaud 

## **Fundraising and Communications Sub-Committee** 

Mrs S McCarthy 

Mr N Patel 

Mr L Thomas 

Mrs K Crabtree (Chair) 

## **Technical Advisory Sub-Committee** 

Mr R Hay (Chair) Ms D Lockwood (co-opted member following retirement) Mr S Walker Ms M Rao (co-opted member) 

Dr Sanjay Singh 

Each Sub-Committee has clear term of reference and is additionally attended by the Chief Executive, the relevant Senior Management Team member and other staff, as agreed by the Sub-Committee’s Chair. The Board and each Sub-Committee meet formally at least four times each year. The agendas for the Board and SubCommittees are set in an annual calendar which itself is reviewed at each meeting of the Board. A Nominations Sub-Committee is convened by the Board Chair for the recruitment of new Trustees and the Chief Executive, the composition at any time being determined by the recruitment task. 

A scheme of delegation is in place, which specifies those matters reserved for the Board and those matters delegated to the Sub-Committees or to the Chief Executive. The terms of reference of the Sub-Committees are regularly reviewed and updated. The Board retains responsibility for the charity’s strategy, annual plan and budget, and the monitoring of these.  The annual plan and budget are the principal means by which implementation of the strategy is delegated to the Chief Executive who is accordingly responsible for the day - to -day running of the charity and, where appropriate, the delegation of budget and operational responsibility to members of the Senior Management Team. 

The remuneration of all key management personnel is determined by the Board, on the recommendation of the Audit Finance and Risk Sub-Committee. In setting the level of remuneration, the Board takes account of available job market and macro-economic data as well as the charity’s financial position. The Charity has subscribed to a job evaluation and remuneration benchmarking service to inform its decision making. 

The Board has benchmarked its governance processes against the Charity Governance Code annually since the current code was introduced in December 2020. The Board considers that it is substantially compliant with the code, although it has identified the need for better processes around equality, diversity and inclusion and has embarked upon a project to bring Lepra’s processes in line with sector best practices, including appropriate training and revised recruitment processes. The Trustee Board attended a full day session in May 2025, where they reflected on their effectiveness and agreed an action plan focused on improvements. 

Trustees are recruited in the light of the skills mix and overall diversity of the Board. Trustee roles are advertised publicly with a clear job and person specification and are shortlisted and interviewed by the Nominations SubCommittee. The Board is responsible for appointing Trustees, in accordance with the Article of Association by 

4 



ordinary resolution and are advised by the Nominations Sub-Committee in this matter. The appointment is confirmed by resolution at the first available general meeting. Trustee terms are determined by the Trustee Terms of Office policy, which currently allows Trustees to serve three terms of three years each. 

The Board has changed in composition during the year as a result of resignations due to personal circumstances and upcoming retirements. All of the Trustees have been carefully selected and offer valuable experience, knowledge and insight from their field and backgrounds, as well as being passionate about our goals. During 2024/2025 the Board undertook a skills and experience audit to ensure that a sufficiently diverse range of skills and perspectives exists to enable the Board to be effective.  Our Trustees volunteer their time and energy towards helping us beat leprosy and LF together. 

New Trustees are required to sign the Lepra Global Code of Conduct and are subject to appropriate criminal records checks. They receive a formal induction including safeguarding training as well as information about the role of a Trustee, both generally and specifically at Lepra. Where possible, Trustees visit offices and engage with staff both in the UK and overseas to understand the charity’s operations and strategy. 

## **GOVERNING DOCUMENT** 

Lepra is a charitable company limited by guarantee, founded in 1924, incorporated on 26 February 1937 and registered as a charity on 4 February 1963. It was established under the Memorandum of Association which established its objects and powers and is governed under its Articles of Association. The Memorandum and Articles of Association were amended by Special Resolutions of the Trustees on 4 June 1957, 7 June 1967, 24 September 1970, 1 July 2008, 15 May 2013, 27 September 2016, 1 October 2019 and 6 May 2022. 

Bangladesh, which is a branch office of the charity which is also registered with the NGO Bureau in Bangladesh. In India we work in partnership with our sister charity, Lepra Society, which is a separate charity registered under the Societies Registration Act and Foreign Contribution (Regulation) Act under Indian law. Lepra Society has an independent Board as required by local legislation. Lepra Society is, however, controlled by the UK charity in accordance with the definitions in FRS102 (Charity SORP) and is therefore considered a subsidiary entity. Lepra therefore prepares group accounts into which the financial results of Lepra Society are consolidated.  The consolidation of accounts is being considered by both Lepra Society and Lepra UK. 

## **PUBLIC BENEFIT STATEMENT** 

Lepra’s objects are contained within the Articles of Association, they are: 

“To carry out the investigation of and promote research into the causes, treatment, cure and prevention of the disease of leprosy and any allied disease and give and grant relief and assistance to any persons suffering or believed to be suffering from, or the family or dependents of such persons of any description, including financial assistance.” 

The articles also grant the charity power to do anything which is calculated to further its Objects(s) or is conducive or incidental to doing so. 

The objects of the charity are reviewed in each iteration of our Global Strategy which is a triennial process. It remains the case that social, mental, and physical health outcomes for many people affected by leprosy and LF) are significantly poorer than for other treatable conditions. Many of those who have developed disabilities as a result of untreated leprosy or LF have poor socioeconomic outcomes. Our research and programmes are designed to improve outcomes at all stages from prevention through to physical, psychological, social and economic care and support. 

The Trustees, from time to time, consider the relevance of Lepra’s objects and whether and how the charity might continue in the future if its Objects were no longer relevant. 

The Trustees are therefore confidently able to state that Lepra has complied with Section 17 of the Charities Act 2011, having due regard to the public benefit guidance issued by the Charity Commission. The Trustees have consulted and adhered to the Commission’s advice, specifically PB1, PB2 and PB3 for the year 2024/25. 

5 



## **OUR STRATEGY AND FUTURE PLANS** 

The financial Year 2025/26 covers the second year of the One Lepra Global Strategy for 2024-2030 and comes at a time when there is concern and anxiety about the future of international aid and development. We continue to operate in a context of ongoing global economic pressures, rising costs, more competition for income, and contracting aid budgets. 

The year ahead therefore focuses on consolidating and strengthening Lepra in line with the Global Strategy’s aims and objectives, as well as building Lepra’s resilience and sustainability and its work for the future. 

Some of our key plans for 2025/26 include: 

**Strengthening One Lepra:** 2025/26 will see accelerated progress towards our One Lepra commitment to strengthen the organisational capacity of our sister charity, LEPRA Society (LS) in India to take on more global leadership for One Lepra. Nurturing and strengthening our partnership of equals, we will finalise the One Lepra Partnership Agreement and support organisational capacity development in key areas, including: governance, fundraising, programme design and delivery, Monitoring and Evaluation (MEAL)and research. We will also be supporting LS in the ongoing development and delivery of its Resource Mobilisation Strategy. This will include: more co-developed fundraising initiatives, with a focus on corporate partnerships especially; fundraising support, training and mentoring of the LS team by the UK fundraising team and closer collaboration on communications between the two organisations. 

## **Scale-back of Lepra Bangladesh** 

Operations in Bangladesh were scaled back in 2024/25, which meant the close-out of all projects except Mind 2 Heart in Bogura, along with the closure of the current Dhaka head office and a move to a smaller, more costeffective office. 

This was not an easy decision, but the Trustees felt it was in the best interests of Lepra to move towards a more financially sustainable model. The scale-back allows us to retain a presence and registration in Bangladesh, providing a platform – albeit much reduced – to continue supporting and advocating for people affected by leprosy and LF. 

## **Developing New Fundraising Focus Areas** 

We will continue our efforts to diversify our UK income across existing and new income streams. In practice this will include, but in no way be limited to, developing our fundraising work with High Net-Worth (HNW) individuals, corporate partners and with the south Asian diaspora communities in the UK. 

## **FUNDRAISING PRACTICES STATEMENT** 

All fundraising was undertaken by staff employed by Lepra as Lepra does not engage third party professional fundraisers to fundraise on its behalf. We do not fundraise via outbound telephone or face to face canvassing and thus are able to exercise control over the risks of donors or potential donors suffering unreasonable pressure and persistence. 

The finance team who process donations, including inbound telephone donations, are aware of the risks around vulnerable donors. We make cancelling regular payments and receipt of newsletters as easy as possible for our supporters. All staff are required to comply with our Ethical Fundraising policy. 

The Chief Executive and all staff are actively engaged in diversifying Lepra’s income sources with specific responsibility assigned to the Director of Fundraising and Communications. 

Lepra is registered with the Fundraising Regulator and has paid the levy thus demonstrating our commitment to good fundraising practice, including ensuring awareness of the need to protect vulnerable donors in line with our safeguarding policy. 

6 



We have committed to abide by the Code of Fundraising Practice and the Fundraising Promise meaning that we commit to high standards, will be clear, honest and open, be respectful, be fair and reasonable and be accountable and responsible. 

All staff, volunteers and Trustees are briefed on the latest version of the Code of Fundraising Practice and compliance is part of relevant staff member’s personal objectives. 

All volunteers, staff and Trustees are obliged to sign and commit to honouring Lepra’s Global Code of Conduct which defines expectations of exemplary behaviour. 

We have an open complaints process, which governs all Lepra staff, volunteers, donors and supporters and is published on our website. During this financial year there were two complaints received about our fundraising practices; one which was resolved within the financial year and the other in the following year. 

Review of fundraising income generation and expenditure and of relevant policies is conducted jointly by the Audit, Finance and Risk Sub-Committee and the Fundraising and Communications Sub-Committee. 

7 



## **PRINCIPAL RISKS AND UNCERTAINTIES** 

The Board of Trustees is responsible for the management of risks and is assisted by the Senior Management Team (SMT) in the day- to -day management of all risks. A strategic risk register is maintained and used to examine and monitor the more significant risks to the organisation. 

The Board delegates the more detailed scrutiny of risk management activity to the Audit, Finance and Risk SubCommittee who review risks quarterly. The full Board reviews the strategic risk register annually and always has access to it. 

Lepra reports risk evaluation and mitigation over three main categories. 

- Strategic risk 

- Operational risk 

- Financial risk 

Within these risk categories, risks are reported in accordance with the approach recommended by the Charity Commission’s guidance (CC26). Risks may be articulated with financial, reputational or environment impacts, or with a combination of impacts. 

## **Fundraising and impact of inflation on the cost base** 

The key risk to Lepra remains the reliance on unrestricted fundraising and legacies to fund its programming, advocacy and research. The risk of inflating costs outweighing increases in income is likely to be an issue both for Lepra and for its many generous donors. Whilst we hold reserves to protect against short term fluctuations in unrestricted income, we also have detailed plans for sustaining our unrestricted income in the longer term, with a particular focus on donor acquisition and diversification of income streams. 

## **Ability to continue our operations in India** 

Lepra Society registration under the Foreign Contributions (Regulation) Act 2020 in India was renewed for five years with effect from 1[st] October 2023 with the result that this risk is now very significantly reduced. This is in no small part due to significant efforts on the part of the India team to ensure compliance with the complex requirements of this legislation. 

## **Ability to demonstrate Impact** 

We believe that there are improvements to be made in the quality of our impact data which will better allow us to demonstrate our impact to donors. This is an issue that is by no means unique to Lepra and is a clear focus of our current global strategy in general and our UK and overseas programmes teams specifically.  Lepra continues to invest in a range of projects to achieve sustainable improvements. 

## **Safeguarding issues** 

A safeguarding system failure could have a serious impact upon our beneficiaries and would cause significant reputational damage to Lepra. We have adopted the best practices recommended by the Charity Commission and the Foreign, Commonwealth and Development Office and as such have embedded safeguarding into our operations and governance. The best systems and policies cannot eliminate the possibility of safeguarding issues arising and the importance of identifying and dealing with issues is key. We continue to update and improve our policies and processes, including our training and reporting frameworks.  We have nominated safeguarding focal points in all countries of operation.  We continue to provide training to our teams in India and Bangladesh. We also have designated safeguarding Trustees in all our countries of operation including a standardised annual safeguarding work plan, which is developed every year. 

## **Fraud risk** 

Offline and online fraud are ever-present risks to charities throughout the delivery chain, and difficult economic environments always lead to an increase in fraud risk generally. The relatively small size of the UK charity creates dependence on a few key individuals, and internal audit processes are being developed that will provide assurance that risk mitigation is optimised.  Globally, we continue to work with our global teams to ensure that transparency and accountability is embedded across the organisation. 

8 



## **Operations in Bangladesh** 

Operations in Bangladesh were scaled back in 2024/25. At the same time, we are embedding systems and processes to reinforce accountability across our operations in that country. 

We continue to seek support from specialist tax advisors to ensure full adherence to local regulatory compliance. In addition, we are reviewing our operating model to secure the long-term financial sustainability of our country programme. 

## **CONTROLS** 

The Trustees have overall responsibility for ensuring that the organisation has appropriate systems of control, financial and otherwise. They are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time, the financial position of the charitable company and enable them to ensure that the Financial Statements comply with the FRS 102 SORP and Companies Act 2006. 

The Trustees recognise that systems of control can only provide a reasonable and not complete assurance against inappropriate or ineffective use of resources, or against the risk of errors or fraud. They remain satisfied that the internal systems provide reasonable assurance that the organisation operates efficiently and effectively, safeguards its assets, maintains proper records and complies with relevant laws and regulations. 

We operate a comprehensive accountability system which includes an annual budget approved by the Trustees. The budget and any subsequent reforecasts are reviewed by the Audit Finance and Risk Sub-Committee, and they consider actual results compared with plans and non- financial performance data. 

In this financial year, our focus was on strengthening and embedding new systems and processes, particularly in the areas of legal compliance and fraud. We also introduced an assurance map to help identify where greater assurance is needed on the effectiveness of controls across these risks. Lepra UK lacks the scale necessary for a dedicated internal audit function within the UK office. However, we continue working with our peers in Bangladesh and India and introduced a peer review process across all operations, expanding on that which already exists in India. We will also continue to seek independent assurance on a case-by-case basis as and when the need arises. 

## **RESERVES** 

We hold reserves as a key part of our strategic risk mitigation. Our reserves policy is approved each year by the Trustees as part of our annual planning and budgeting process. 

## **What is our safe level of unrestricted reserves?** 

In order to ensure that colleagues in India and Bangladesh can maintain and develop infrastructure, we commit to a certain level of funding when the annual plan is agreed in February each year. This is largely funded out of that year’s unrestricted income. We hold £400k of UK charity reserves to cover volatility in unrestricted fundraising, particularly around legacies and the considerable risks to our fundraising from a rapidly deteriorating economic outlook. 

## **Designation of reserves to support the Global Strategy plan** 

The delivery of our Global Strategy Plan required an annual drawdown of £200k from unrestricted reserves. The Board agreed to designate unrestricted reserves of £400k to support the strategy. The designation was to cover the additional costs of implementing the Plan compared to the recurrent expenditure inherent in programme delivery. A significant deficit budget was approved by the Board in 2024 for the delivery of the Global Strategy for 2024-29.  These designated funds were released in the year. 

## **Designation of unrestricted funds** 

We designated £225k of unrestricted reserves to the ASPIRE project in 2020/21, a five-year collaboration with Effect Hope aimed at reducing the incidence and impact of a number of neglected tropical skin diseases, including Leprosy and LF, in Bihar, India. A formal agreement to this effect was signed by both parties on 1st July 2021. The balance of this fund at the end of the year was £37k. 

9 



Against the total UK Charity reserves requirement of £400k, the free reserves of the UK Charity were £906k at 31st March 2025. The group free reserves were £2,127k the additional reserves held by LS equating to approximately 12 months’ running costs, providing a contingency buffer against any difficulties experienced remitting funding from the UK to India. 

## **GOING CONCERN** 

Lepra’s current and forecasted unrestricted reserves and cash position is above the target levels set out in its reserves policy and our generation of unrestricted funding has remained robust. The Trustees have a reasonable expectation, that the Charity has adequate resources to continue operating for the foreseeable future. Thus, they continue to adopt the going concern basis in preparing the financial statements. 

## **GRANT MAKING POLICY** 

Lepra works principally through its branch in Bangladesh and its sister charity, Lepra Society in India. In addition, payments are made to other charities in relation to joint projects and collaborations. The funding for all these projects is approved by the Board when it approves the annual budget. Consequently, unsolicited applications for grants are not invited from other organisations. 

## **INVESTMENTS POLICY** 

Lepra seeks the best returns on investment commensurate with its risk appetite. The investment objective for short term funds is to preserve capital value with minimal risk, and a plan is in the process of implementation to meet this objective. Assets should be readily realisable to meet unanticipated cash requirements in excess of planned expenditure. 

A small portfolio of investments is held in accordance with powers of the Trustees. Investments are either listed or readily realisable and acquired through generous donation from our supporters with the exception of unlisted shares in Helpcards Holdings Ltd in which Lepra holds 6.74% of the issued share capital. Except for the investment in Helpcards Holdings Ltd, which is a strategic investment, the Trustees have authorised the disposal of all readily realisable equity investments at the earliest opportunity, subject to cost. 

## **SAFEGUARDING POLICY** 

Lepra promotes best practice in safeguarding its beneficiaries, staff and volunteers. A Trustee and executive director are designated with responsibility for safeguarding, and it is a standing item on all Board and Senior Management Team meeting agendas. All staff, Trustees and volunteers are subject to appropriate checks, are required to sign the Global Code of Conduct and receive safeguarding training. This is supported with robust complaints and whistleblowing policies. There was a safeguarding incident during 2024/25 that was reported to the Charities Commission, which noted the incident with no further action.  Lepra continues to work with our overseas staff to ensure that safeguarding processes are in place and are adhered to. 

## **DATA PROTECTION POLICY** 

Lepra has robust policies and procedures to protect and control the personal data of donors, supporters and employees. Specific policies govern the handling of personal data and use of IT systems with monitoring of compliance in accordance with the Data Protection Act 2018. All staff and volunteers are trained in data protection during induction 

10 



## **FINANCIAL REVIEW** 

Total income for the year ended 31 March 2025 was £5.9m, an increase of £977k compared to prior year. This is largely due to an increase in both unrestricted and restricted income. 

Unrestricted income for the charity excluding legacies increased by £249k in total compared to the prior year, which was due to an increase in Trusts & Corporate, Community and Events.  There was a decrease in individual giving income of £23k. 

Overall, the group’s unrestricted income increased by £556k. 

Restricted income, at £2.09m was up by £421k compared to prior year.  This is largely due to increased income from funding agencies. 

Despite the challenging economic circumstances that many of our donor’s face, we remain humbled by their continuing support and the generosity of their bequests. 

Total expenditure from unrestricted funds was £3.68m, an increase of £177k compared to prior year. This is expected due to the investment in the country programmes in both India and Bangladesh as part of the Global Strategic plan. 

Overall, a group surplus of £390k on unrestricted funds was generated and this was partly due to the release of the Designated funds and an increase in legacy, trusts and corporate income. Group cash decreased by £217k. 

Group cash balances at year end were £1.4m and Group Funds were £5.48m. 

## **STATEMENT OF TRUSTEES’ RESPONSIBILITIES** 

The Trustees (who are also directors of Lepra under company law) are responsible for preparing the annual report (including strategic report) and the financial statements in accordance with applicable laws and regulations. 

Company law requires Trustees to prepare financial statements in accordance with UK Generally Accepted Accounting Practice which give a true and fair view of the state of affairs of the company and of the incoming resources and application of resources, including income and expenditure for that period. In preparing these financial statements, the Trustees are required to: 

- Select suitable accounting policies and apply them consistently; 

- Observe methods and principles in the Charities’ SORP; 

- Make judgements and estimates that are reasonable and prudent; 

- State whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and 

- Prepare the financial statements on a going concern basis unless it is inappropriate to presume that the company will continue in business. 

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the company’s transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, and the Charities Accounts (Scotland) Regulations 2006 (as amended). 

They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. 

The Trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company’s website. 

Legislation in the UK governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions. 

In so far as the Trustees are aware: 

- There is no relevant audit information of which the company’s auditor is unaware; and 

11 



- The Trustees have each taken all steps that they ought to have taken as a Trustee in order to make them aware any relevant audit information, and to establish that the company’s auditors are aware of that information. 

Approved by the Board of Trustees on the 30[th] of September 2025 including in their capacity as company directors the strategic report contained therein and signed on its behalf by: 

Suzanne McCarthy Chair 


Lepra (Company no 324748) 

12 



**INDEPENDENT AUDITOR’S REPORT TO THE TRUSTEES AND MEMBERS OF LEPRA** 

## **Opinion** 

We have audited the financial statements of Lepra (‘the charitable company’) and its subsidiaries (‘the group’)] for the year ended 31 March 2025 which comprise Consolidated Statement of Financial Activities, Consolidated Balance Sheet, Consolidated Cash Flow Statement, Charity Statement of Financial Activities, Charity Balance Sheet, Charity Cash Flow Statement and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice). 

In our opinion the financial statements: 

- give a true and fair view of the state of the group’s and the charitable company’s affairs as at 31 March 2025 and of the group’s income and expenditure, for the year then ended; 

- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and 

- have been prepared in accordance with the requirements of the Companies Act 2006 and the Charities and Trustee Investment (Scotland) Act 2005 and Regulations 6 and 8 of the Charities Accounts (Scotland) Regulations 2006 (amended). 

## **Basis for opinion** 

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the financial statements section of our report. We are independent of the group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. 

## **Conclusions relating to going concern** 

In auditing the financial statements, we have concluded that the trustee's use of the going concern basis of accounting in the preparation of the financial statements is appropriate. 

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's or the group’s ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue. 

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report. 

## **Other information** 

The trustees are responsible for the other information contained within the annual report. The other information comprises the information included in the annual report, other than the financial statements and our auditor’s report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. 

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. 

13 



We have nothing to report in this regard. 

## **Opinions on other matters prescribed by the Companies Act 2006** 

In our opinion based on the work undertaken in the course of our audit 

- the information given in the trustees’ report, which includes the directors’ report and the strategic 

- report prepared for the purposes of company law, for the financial year for which the financial statements are prepared is consistent with the financial statements; and 

- the strategic report and the directors’ report included within the trustees’ report have been prepared 

- in accordance with applicable legal requirements. 

## **Matters on which we are required to report by exception** 

In light of the knowledge and understanding of the group and charitable company and their environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the directors’ report included within the trustees’ report. 

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 and the Charities Accounts (Scotland) Regulations 2006 require us to report to you if, in our opinion: 

- adequate and proper accounting records have not been kept; or 

- the financial statements are not in agreement with the accounting records and returns; or 

- certain disclosures of trustees' remuneration specified by law are not made; or 

- we have not received all the information and explanations we require for our audit. 

## **Responsibilities of trustees** 

As explained more fully in the trustees’ responsibilities statement set out on page 12, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. 

In preparing the financial statements, the trustees are responsible for assessing the charitable company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so. 

## **Auditor’s responsibilities for the audit of the financial statements** 

We have been appointed as auditor under section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with the Acts and relevant regulations made or having effect thereunder. 

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. 

Details of the extent to which the audit was considered capable of detecting irregularities, including fraud and non-compliance with laws and regulations are set out below. 

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council’s website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report. 

## **Extent to which the audit was considered capable of detecting irregularities, including fraud** 

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We identified and assessed the risks of material misstatement of the financial statements from irregularities, whether due to fraud or error, and discussed these between our audit team members. We then designed and performed audit 

14 



procedures responsive to those risks, including obtaining audit evidence sufficient and appropriate to provide a basis for our opinion. 

We obtained an understanding of the legal and regulatory frameworks within which the charitable company and group operates, focusing on those laws and regulations that have a direct effect on the determination of material amounts and disclosures in the financial statements. The laws and regulations we considered in this context were the Companies Act 2006 and The Charities and Trustee Investment (Scotland) Act 2005 together with the Charities SORP (FRS102) 2019. We assessed the required compliance with these laws and regulations as part of our audit procedures on the related financial statement items. 

In addition, we considered provisions of other laws and regulations that do not have a direct effect on the financial statements but compliance with which might be fundamental to the charitable company’s and the group’s ability to operate or to avoid a material penalty. We also considered the opportunities and incentives that may exist within the charitable company and the group for fraud. The laws and regulations we considered in this context for the UK operations were Anti-fraud, bribery and corruption legislation, taxation legislation. We also considered compliance with local legislation for the group’s overseas operating segments. 

Auditing standards limit the required audit procedures to identify non-compliance with these laws and regulations to enquiry of the Trustees and other management and inspection of regulatory and legal correspondence, if any. 

We identified the greatest risk of material impact on the financial statements from irregularities, including fraud, to be within the timing of recognition of grant and legacy income, going concern and the override of controls by management. Our audit procedures to respond to these risks included enquiries of management, and the Audit, Finance & Risk Committee about their own identification and assessment of the risks of irregularities, performing sample testing on grant and legacy income, sample testing on the posting of journals, reviewing accounting estimates for biases, reviewing regulatory correspondence with the Charity Commission, OSCR, detailed review of budgets and forecasts and reading minutes of meetings of those charged with governance. 

Owing to the inherent limitations of an audit, there is an unavoidable risk that we may not have detected some material misstatements in the financial statements, even though we have properly planned and performed our audit in accordance with auditing standards. For example, the further removed non-compliance with laws and regulations (irregularities) is from the events and transactions reflected in the financial statements, the less likely the inherently limited procedures required by auditing standards would identify it. In addition, as with any audit, there remained a higher risk of non-detection of irregularities, as these may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls. We are not responsible for preventing non-compliance and cannot be expected to detect non-compliance with all laws and regulations. 

15 



## **Use of our report** 

This report is made solely to the charitable company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006, and to the charitable company’s trustees, as a body, in accordance with Regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charitable company’s members those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company’s members as a body and the charitable company’s trustees as a body, for our audit work, for this report, or for the opinions we have formed. 


## **Tara Westcott** 

Senior Statutory Auditor For and on behalf of Crowe U.K. LLP Statutory Auditor 4th Floor St James House St James Square Cheltenham, GL50 3PR Date: 8 October 2025 

16 



## **Lepra** 

## **CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES** 

## **YEAR ENDED 31 MARCH 2025** 

|Note<br>**Unrestricted**<br>**Funds**<br>**Restricted**<br>**Funds**<br>**Designated**<br>**Funds**<br>**Total**<br>**2025**<br>**£**<br>**£**<br>**£**<br>**£**<br>**Income from:**<br>Donations and<br>legacies<br>6<br>3,654,249<br>76,663<br>-<br>3,730,912<br>Charitable activities<br>6<br>14,339<br>2,001,309<br>-<br>2,015,648<br>Investments<br>6<br>118,379<br>-<br>-<br>118,379<br>Other<br>6<br>35,445<br>9,361<br>-<br>44,806<br>**Total income**<br>3,822,412<br>2,087,333<br>-<br>5,909,745<br>**Expenditure on:**<br>Raising funds<br>8<br>533,543<br>-<br>-<br>533,543<br>Charitable activities<br>8<br>3,144,210<br>1,930,226<br>54,175<br>5,128,611<br>**Total expenditure**<br>3,677,753<br>1,930,226<br>54,175<br>5,662,154<br>Net gains / (losses) on<br>investments<br>10/12<br>(47,008)<br>-<br>-<br>(47,008)<br>**Net income /**<br>**(expenditure)**<br>97,651<br>157,107<br>(54,175)<br>200,583<br>**Transfers between**<br>**funds**<br>18<br>400,000<br>-<br>(400,000)<br>-<br>**Other recognised gains /**<br>**(losses):**<br>(Losses)/Gains on foreign<br>currency transactions<br>(108,499)<br>-<br>-<br>(108,499)<br>**Total other**<br>**(Losses)/Gains**<br>(108,499)<br>-<br>-<br>(108,499)<br>**Net movement in**<br>**funds**<br>389,152<br>157,107<br>(454,175)<br>92,084<br>**Reconciliation of**<br>**funds:**<br>Total funds brought<br>forward<br>4,693,906<br>205,171<br>491,525<br>5,390,602<br>**Total funds carried**<br>**forward**<br>5,083,058<br>362,278<br>37,350<br>5,482,686|**Unrestricted**<br>**Funds**<br>**Restricted**<br>**Funds**<br>**Designated**<br>**Funds**<br>**Total**<br>**2024**<br>**£**<br>**£**<br>**£**<br>**£**<br>3,028,043<br>126,176<br>-<br>3,154,219<br>138,603<br>1,540,579<br>-<br>1,679,182<br>76,915<br>-<br>-<br>76,915<br>22,408<br>-<br>-<br>22,408|
|---|---|
||3,265,969<br>1,666,755<br>-<br>4,932,724<br>478,732<br>-<br>-<br>478,732<br>3,022,326<br>1,649,112<br>59,023<br>4,730,461|
||3,501,058<br>1,649,112<br>59,023<br>5,209,193<br>14,797<br>-<br>-<br>14,797|
||(220,292)<br>17,643<br>(59,023)<br>(261,672)<br>-<br>-<br>-<br>-<br>(70,188)<br>-<br>-<br>(70,188)|
||(70,188)<br>-<br>-<br>(70,188)|
||(290,480)<br>17,643<br>(59,023)<br>(331,860)<br>4,984,386<br>187,528<br>550,548<br>5,722,462<br>4,693,906<br>205,171<br>491,525<br>5,390,602|



All gains and losses arising in the year are included above and arise from continuing actives. 

The notes on pages 24- 49 form part of these financial statements. Company registration number:00324748 

17 



## **Lepra** 

**CONSOLIDATED BALANCE SHEET Company registration number 00324748 YEAR ENDED 31 MARCH 2025** 

|**Note**<br>**FIXED ASSETS**<br>Tangible assets<br>9<br>Investment Property<br>10<br>Intangible assets<br>11<br>Investments<br>12<br>**CURRENT ASSETS**<br>Stocks<br>14<br>Debtors<br>15<br>Investments<br>Cash at bank and in hand<br>**CREDITORS:**<br>Amounts falling due within one year<br>16<br>**NET CURRENT ASSETS**<br>**TOTAL ASSETS LESS CURRENT**<br>**LIABILITIES**<br>**TOTAL NET ASSETS**<br>**FUNDS**<br>Unrestricted funds – general<br>18<br>Unrestricted funds – designated<br>20<br>Restricted funds<br>19|**£**<br>26,686<br>604,491<br>675,451<br>1,422,313|**2025**<br>**£**<br>2,618,683<br>275,495<br>2,755<br>59,315|**2024**<br>**£**<br>**£**<br> <br>2,517,743<br>283,770<br> <br>10,219<br> <br>66,494<br>2,878,226<br>30,975<br>449,645<br>631,342<br>1,639,137<br>2,751,099<br>(238,723)<br>2,512,376<br>5,390,602<br>5,390,602<br>4,693,906<br>491,525<br>205,171<br>5,390,602|**2024**<br>**£**<br>**£**<br> <br>2,517,743<br>283,770<br> <br>10,219<br> <br>66,494<br>2,878,226<br>30,975<br>449,645<br>631,342<br>1,639,137<br>2,751,099<br>(238,723)<br>2,512,376<br>5,390,602<br>5,390,602<br>4,693,906<br>491,525<br>205,171<br>5,390,602|
|---|---|---|---|---|
|||2,956,248<br>||2,878,226<br> <br> <br>|
||2,728,941<br>(202,503)||2,751,099<br>(238,723)||
|||2,526,438||2,512,376|
|||5,482,686||5,390,602|
|||5,482,686||5,390,602|
|||5,083,058<br>37,350<br>362,278||4,693,906<br>491,525<br>205,171|
|||5,482,686||5,390,602|



The financial statements were approved by the Trustees and authorised for issue on 30[th] September 2025. The group’s overall gains for 2025 were £92,084 for 2025 (£331,860 2024) 


Mrs S Bhasin, Hon Treasurer 

The notes on pages 24-49 form part of these financial statements. 

18 



## **Lepra** 

## **CONSOLIDATED CASH FLOW STATEMENT** 

|**YEAR ENDED 31 MARCH 2025**<br>**Statement of cash flows**<br>**Cash flows from operating activities:**<br>**Net cash used in operating activities**<br>**Cash flows from investing activities:**<br>Dividends and interest<br>Purchase of fixed assets<br>Net cash used in investing activities<br>**Cash flows from financing activities:**<br>Change in cash and cash equivalents<br>Opening cash and cash equivalents<br>Change in cash and cash equivalents due to exchange rate movements<br>**Cash and cash equivalents at 31 March**<br>Reconciliation of net income (expenditure) to net cash flow from operating activities:<br>Net income (expenditure) for the period (as per SOFA)<br>Adjustments for:<br>Depreciation charges<br>Losses (Gains)/on investments<br>Dividends and interest<br>Profit on sale of fixed assets<br>Decrease (Increase)/ in stocks<br>Foreign exchange difference on opening reserves<br>Corpus Fund LS<br>(Increase) in debtors<br>(Increase) in short term investments<br>(Increase)/Decrease in creditors<br>**Net cash used in operating activities**|**2025**<br>**2024**<br>**£**<br>**£**<br>151,181<br> (134,589)|
|---|---|
||118,379<br>76,915<br>(377,885)<br>(537,096)|
||(259,506)<br>(460,181)|
||(108,325)<br>(594,770)<br>1,639,137<br>2,304,095<br>(108,499) <br>(70,188)|
||1,422,313<br>1,639,137|
||2025<br>2024<br>£<br>£<br>200,583<br>(261,672)<br>245,342<br>247,804<br>47,008<br>(15,736)<br>(118,379)<br>(76,915)<br>783<br>3,760<br>4,289<br>(5,953)<br>(2,635)<br>9,365<br>3,101<br>-<br>(154,846)<br>(39,577)<br>(44,109)<br>(5,198)<br>(36,220)<br>15,797|
||151,181<br> (134,589)|



19 



## **Lepra** 

## **CHARITY STATEMENT OF FINANCIAL ACTIVITIES** 

## **YEAR ENDED 31 MARCH 202** 5 

||**Note**|**Unrestricted**|**Restricted**|**Designated**|**Total**|**Unrestricted**|**Restricted**|**Designated**|**Total**|
|---|---|---|---|---|---|---|---|---|---|
|||**Funds**|**Funds**|**Funds**|**2025**|**Funds**|**Funds**|**Funds**|**2024**|
|||**£**|**£**||**£**|**£**|**£**||**£**|
|**Income from:**||||||||||
|**Donations and**|6|||||1,747,229|105,263|-|1,852,492|
|**legacies**||2,140,851|76,663|-|2,217,514|||||
|**Charitable activities**|6|-|269,499|-|269,499|138,602|246,158|-|384,760|
|**Investments**|6|38,790|-|-|38,790|13,017|-|-|13,017|
|**Other**|6|35,445|-|-|35,445|22,408|-|-|22,408|
|**Total income**||2,215,086|346,162|-|2,561,248|1,921,256|351,421|-|2,272,677|
|**Expenditure on:**||||||||||
|**Raising funds**|8|533,543|-|-|533,543|478,732|-|-|478,732|
|**Charitable activities**|8|1,814,603|331,972|54,175|2,200,750|1,976,688|374,558|59,023|2,410,269|
|**Total expenditure**||2,348,146|331,972|54,175|2,734,293|2,455,420|374,558|59,023|2,889,001|
|**Net gains / (losses) on**|10/12|(47,008)|-|-|(47,008)|14,797|-|-|14,797|
|**investments**||||||||||
|**Net income /**||(180,068)|14,190|(54,175)|(220,053)|(519,367)|(23,137)|(59,023)|(601,527)|
|**(expenditure)**||||||||||
|**Transfers between**|18|400,000|-|(400,000)|-|-|-|-|-|
|**funds**||||||||||
|**Other recognised gains**|**/**|||||||||
|**(losses):**||||||||||
|**Gains (Losses) on foreign**||(11,283)|-|-|(11,283)|(34,550)|-|-|(34,550)|
|**currency transactions**||||||||||
|**Total other gains /**||(11,283)|-|-|(11,283)|(34,550)|-|-|(31,164)|
|**(losses)**||||||||||
|**Net movement in**||208,649|14,190|(454,175)|(231,336)|(553,917)|(23,137)|(59,023)|59,827|
|**funds**||||||||||
|**Reconciliation of**||||||||||
|**funds:**||||||||||
|**Total funds brought**||1,816,613|23,429|491,525|2,331,567|2,370,530|46,566|550,548|2,967,644|
|**forward**||||||||||
|**Total funds carried**||2,025,262|37,619|37,350|2,100,231|1,816,613|23,429|491,525|2,331,567|
|**forward**||||||||||



All gains and losses arising in the year are included above and arise from continuing activities. 

The notes on pages 24-49 form part of these financial statements 

20 



## **Lepra** 

## **CHARITY BALANCE SHEET Company registration number 00324748 YEAR ENDED 31 MARCH 2025** 

|**Note**<br>**FIXED ASSETS**<br>Tangible assets<br>9<br>Investment Property<br>10<br>Intangible assets<br>11<br>Investments<br>12<br>**CURRENT ASSETS**<br>Debtors<br>15<br>Cash at bank and in hand<br>**CREDITORS:**<br>Amounts falling due within one year<br>16<br>**NET CURRENT ASSETS**<br>**TOTAL ASSETS LESS CURRENT LIABILITIES**<br>**TOTAL NET ASSETS**<br>**FUNDS**<br>Unrestricted funds - general<br>18<br>Unrestricted funds - designated<br>20<br>Restricted funds<br>19|**2025**<br>**£**<br>**£**<br>800,116<br>275,495<br>2,722<br>40,527<br>1,118,860<br>343,090<br>796,327<br>1,139,417<br>(158,046)<br>981,371<br>2,100,231<br>2,100,231<br>2,025,262<br>37,350<br>37,619<br>2,100,231|**2025**<br>**£**<br>**£**<br>800,116<br>275,495<br>2,722<br>40,527<br>1,118,860<br>343,090<br>796,327<br>1,139,417<br>(158,046)<br>981,371<br>2,100,231<br>2,100,231<br>2,025,262<br>37,350<br>37,619<br>2,100,231|**2024**<br>**£**<br>**£**<br> <br>860,550<br> <br>283,770<br>10,186<br>40,977<br>1,195,483<br>122,894<br>1,148,472<br>1,271,366<br>(135,282)<br>1,136,084<br>2,331,567<br>2,331,567<br>1,816,613<br>491,525<br>23,429<br>2,331,567|**2024**<br>**£**<br>**£**<br> <br>860,550<br> <br>283,770<br>10,186<br>40,977<br>1,195,483<br>122,894<br>1,148,472<br>1,271,366<br>(135,282)<br>1,136,084<br>2,331,567<br>2,331,567<br>1,816,613<br>491,525<br>23,429<br>2,331,567|
|---|---|---|---|---|
|||1,118,860<br> <br> <br>||1,195,483|
||1,139,417<br>(158,046)||1,271,366<br>(135,282)||
|||981,371||1,136,084|
|||2,100,231||2,331,567|
|||2,100,231||2,331,567|
|||2,025,262<br>37,350<br>37,619||1,816,613<br>491,525<br>23,429|
|||2,100,231||2,331,567|



The financial statements were approved by the Trustees and authorised for issue on 30[th] September 2025 


Mrs S Bhasin Hon Treasurer 

The notes on pages 24-49 form part of these financial statements. 

21 



**Lepra** 

## **CHARITY CASH FLOW STATEMENT** 

## **YEAR ENDED 31 MARCH 2025** 

|**Statement of cash flows**<br>**Cash flows from operating activities:**<br>**Net cash used in operating activities**<br>**Cash flows from investing activities:**<br>Dividends and interest<br>Purchase of fixed assets<br>Net cash used in investing activities<br>Net cash used in financing activities<br>Change in cash and cash equivalents<br>Opening cash and cash equivalents<br>Change in cash and cash equivalents due to exchange rate<br>movements<br>**Cash and cash equivalents at 31 March**<br>Reconciliation of net income (expenditure) to net cash flow<br>from operating activities:<br>Net income (expenditure) for the period (as per SOFA)<br>Adjustments for:<br>Depreciation charges<br>(Gains)/losses on investments<br>Dividends and interest<br>Loss/ (profit) on sale of fixed assets<br>Decrease/(increase) in debtors<br>Increase/(decrease) in creditors<br>**Net cash used in operating activities**||**2025**<br>**2024**<br>£<br>£<br>(369,867)<br>(574,367)|
|---|---|---|
|||38,790<br>13,017<br>(9,785)<br>(16,317)<br>29,005<br>(3,300)|
|||-<br>-|
|||(340,862)<br>(577,667)<br>1,148,472<br>1,760,689<br>(11,283)<br>(34,550)|
|||796,327<br>1,148,472|
|||2025<br>2024<br>£<br>£<br>(220,053)<br>(601,527)<br>39,634<br>50,538<br>47,008<br>(14,797)<br>(38,790)<br>(13,017)<br>(234)<br>-<br>(220,196)<br>75,389<br>22,764<br>(70,953)|
|||(369,867)<br>(574,366)|



22 



**Lepra** 

## **NOTES TO THE FINANCIAL STATEMENTS** 

## **YEAR ENDED 31 MARCH 2025** 

- 1 STATUS 

The Company is limited by guarantee and has no share capital.  The liability of each member is determined by the constitution of the Association and shall not exceed the sum of £1. The charity was incorporated in the United Kingdom, registered office is 28 Middleborough, Colchester, CO1 1TG. Charity number 213251. Company registration number 00324748. 

- 2 ACCOUNTING POLICIES 

   - a) The financial statements have been prepared under the historical cost convention. The financial statements have been prepared in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102). The Charitable Company is a public benefit company for the purposes of FRS 102 and therefore the Charity also prepared its financial statements in accordance with the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (The FRS 102 Charities SORP), the Companies Act 2006 and the Charities Act 2011. 

The trustees have assessed whether the use of the going concern basis is appropriate and have considered possible events or conditions that might cast significant doubt on the ability of the charity and group to continue as a going concern. The trustees have made this assessment for a period of at least one year from the date of approval of the financial statements. During the financial year, the charity has continued to show the resilience of its unrestricted income streams, and whilst the current economic environment is challenging, we have significant cash and unrestricted reserves and our operations in the UK and in India and Bangladesh are sufficiently scalable to respond to unforeseen reductions in income. The Trustees believe that over a 1-2 year timescale, release of cash reserves, our unrestricted fundraising donor base, our legacy pipeline and ability to scale back programming operations together provide a reasonable expectation that the charity and group has adequate resources to continue in operational existence for the foreseeable future. The charity and group therefore continues to adopt the going concern basis in preparing its financial statements. 

- b) Quoted fixed asset investments are recorded on the Balance Sheet at bid price values at the year end. The unquoted investments are recorded at the valuation determined by the Trustees. 

- c) Realised gains and losses arising from the disposal of fixed asset investments are calculated as the difference between the net sale or redemption proceeds and either the market value at the last balance sheet date or the cost of investments purchased during the year. 

- d) Unrealised gains and losses arising on the revaluation of fixed asset are considered immaterial and are taken straight to the unrestricted reserves rather than via a specific revaluation reserve. 

- e) Income recognition - Income tax recoverable on gift-aided donations is calculated and accrued based upon income received during the financial year. Legacies are recognised at the earlier of the point that estate accounts have been received, or the cash has been received. 

   - Under this accounting policy, in the absence of payment, legacies are only accrued on receipt of finalised estate accounts or where it is judged that there is sufficient other evidence that the legacy can be reliably estimated. Reversionary interests involving a life tenant and discretionary trusts are not recognised. 

Donations are reported on a receivable basis. 

Grants receivable where related to performance and specific deliverables, is accounted for as the Charity earns the right to consideration by its performance. Where Income is received in advance of performance, its recognition is deferred and included in creditors. Where entitlement occurs before income is received, the income is accrued. 

- f) Resources expended are allocated to the particular activities where the cost relates directly to that activity. Support Costs are allocated as the costs that are identified as a direct support to an activity. The activities and allocations included resources expended was updated last year to better reflect how the charity now receives income and the work that we do. Central costs are apportioned on a staff time basis as follows: Programmes 49.17%, Research 1.67%, Advocacy 11.04%, Education 10.42%, Leprosy Review 3.73% Database Fundraising 16.88%, Events 2.92% and Institutions & Trusts 4.17%. 

23 



**Lepra** 

## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** 

## **YEAR ENDED 31 MARCH 2025** 

- g) Property that is held for long-term rental or is being developed for future rental is classified as investment property. The fair value of the land and buildings is determined by a market-based appraisal undertaken by a professionally qualified valuer every year and the next valuation will be undertaken in 2026 to reflect changes in license to occupy footage. Changes in fair value are recognised in the Statement of Financial Activity. Assets are reviewed annually for any impairment in value. 

- h) All assets purchased are valued at cost. UK assets purchased below £500 are not capitalised and are shown as a revenue cost. 

Depreciation is charged on the Organisation’s fixed assets at the following rates, which are expected to reduce the assets to their net realisable values over their estimated useful lives. 

|Freehold Building||Over 50 years|
|---|---|---|
|Motor vehicles||25% per annum on cost|
|Office equipment||20% per annum on cost|
|Computer equipment||25% per annum on cost|
|LEPRA India|Leasehold|Over the life of the lease|
||Freehold Buildings|10%|
||Vehicles and equipment|15%|
||Medical equipment|15%|
||Furniture|10%|
||Computer equipment|40%|
||Intangible Assets|25%|



Depreciation is provided for the full year on the written down value method, at the above rates as prescribed in the Indian Income Tax Act, 1961. 

|LEPRA Bangladesh|Furniture|15% per annum reducing balance|
|---|---|---|
||Office equipment|15% per annum reducing balance|
||Bicycle|20% per annum reducing balance|
||Motor vehicles/cycles|<br>20% per annum reducing balance|
||Computer equipment|33% per annum reducing balance|



- i) Freehold property at 28 Middleborough, Colchester CO1 1TG was purchased on 4 November 2004. This, together with the contracted works, has been fully recognised in the accounts. 

- j) Computer software is stated at cost less accumulated amortisation and accumulated impairment losses. Computer software is amortised over its estimated useful life of 4 years, on a straight-line basis. 

- k) Other financial instruments 

   - i. Cash and cash equivalents: 

      - Cash and cash equivalents include cash at banks and in hand and short-term deposits with a maturity date of three months or less. 

   - ii. Debtors and creditors: Debtors and creditors receivable or payable within one year of the reporting date are carried at the at transaction price. Debtors and creditors that are receivable or payable in more than one year and not subject to a market rate of interest are measured at the present value of the expected future receipts or payment discounted at a market rate of interest. 

- l) Foreign currency balances have been converted at the exchange rate ruling at 31 March 2025. Transactions during the year are included at the average rate for the year in which the transaction occurred. With regard to the accounts of overseas branch and subsidiary undertakings these are translated into sterling on the following basis: 

   - Assets and liabilities are at the rate of exchange ruling at the year-end date. Income and Expenditure account items at the average rate of exchange for the year. 

   - All exchange differences arising on the translation into sterling are recognised through the Statement of Financial Activities. 

24 



## **Lepra** 

## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** 

## **YEAR ENDED 31 MARCH 2025** 

|m)|Grant expenditure on programmes and research is accounted for in the period when payable and sums|
|---|---|
||unpaid at the balance sheet date are included in current liabilities.|
|n)|Deferred income relates to income received during the financial year which has been restricted by the|
||donor to be spent in a future accounting period.|
|o)|Critical accounting estimates and areas of judgement–- in the view of the trustees in applying the|
||accounting policies adopted, an accounting estimate is applied to the legacy accrual (£225,472) as legacies|
||are accrued based on estate accounts. An accounting judgement is taken on whether the charity is entitled|
||to grant income received in the year (£269,499).|
|p)|Lepra operates a defined contribution pension scheme for its employees. The contributions are paid|
||monthly as they fall due. The expense to activity allocation matches the wage to activity allocation. Pension|
||costs are treated as unrestricted unless a specific restricted gift was received for that purpose.|
|q)|Fund accounting|
||Funds held by the charity are:|
||Unrestricted general funds – these are funds that can be used in accordance with the charitable objects at|
||the discretion of the Trustees.|
||Restricted funds – these are funds that can only be used for a particular purpose within the objects of the|
||charity. Restrictions arise when specified by the donor or when funds are raised for specific restricted|
||purposes.|



Designated funds – these are funds which have been designated for specific purposes by the Lepra Trustees. Further explanations of the nature and purpose of each fund is included in the notes to the accounts. 

- r) Stock is valued at the lower of cost or net realisable value. 

- s) Current asset investments consist of short-term deposits with a maturity date of more than 3 months but less than 12 months. Any deposits with a maturity date of more than 12 months are included within fixed asset investments. 

- t) Donated services and facilities relate to medical equipment provided to Lepra Society India and are valued at cost price. 

- u) Rentals applicable to operating leases where substantially all of the benefits and risks of ownership remain with the lessor are charged to the SOFA on a straight-line basis over the lease term. 

## **4 BASIS OF CONSOLIDATION** 

The Group financial statements consolidate the financial statements of the Charity and its subsidiary undertaking for the year. Lepra (Society) India is consolidated in these financial statements as a subsidiary.  Lepra (Society) India is considered to be a subsidiary, within the requirements outlined in SORP FRS102 section 24.16, because Lepra has the power to govern financial and operating policies as set out in specific clauses included within the Lepra (Society) India memorandum and, in the event of dissolution, remaining assets will be transferred to Lepra. 

All financial statements are made up to 31 March 2025. All intra-group transactions, balances and unrealised gains on transactions between group entities are eliminated on consolidation. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred. Where necessary, adjustments are made on consolidation to bring the accounting policies used into line with those used by other members of the group. 

Lepra Bangladesh is treated as a branch of Lepra and forms part of the Charity financial statements. 

The summary financial statements of Lepra India are shown in Note 5. 

25 



**Lepra** 

**YEAR ENDED 31 MARCH 2025** 

## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** 

## **5          SUBSIDIARIES SUMMARY FINANCIAL STATEMENTS** 

## **LEPRA SOCIETY OF INDIA** 

Lepra has common objects and activities to the “LEPRA Society of India” (hereafter called LEPRA India).  LEPRA India is a registered charity, Charity Registration number 474 of 1989 under the Andhra Pradesh Public Societies Registration Act 1350 Fasli and having its offices at Plot No 17, Krishnapuri Colony, West Marredpally, Secunderabad 500-026, India **.** 

The Chairman of the Organisation’s Trustees and of its Medical Advisory Board, plus the Chief Executive of LEPRA UK are exofficio members of the Management Committee of LEPRA India.  LEPRA India determines its own policies governing its leprosy control and related work in India and is free to raise funds in India in future; but currently, and for the foreseeable future, LEPRA India is dependent on Lepra for its funding support under a mutually agreed annual budget. 

## **LEPRA INDIA INCOME & EXPENDITURE ACCOUNT** 

|Income:<br>Grants from UK<br>Other income<br>Expenditure:<br>(Losses)/gains on foreign currency translation<br>Net movement in funds<br>Balance at 31 March 2024<br>Corpus Fund<br>Balance at 31 March 2025<br>**LEPRA INDIA BALANCE SHEET**<br>Tangible Fixed Assets<br>Fixed Asset Investment<br>Current Assets<br>Investments<br>Stock<br>Debtors<br>Cash at bank & in hand<br>Creditors: Amounts falling due within one year<br>SER Revolving Fund<br>Restricted Fund & Corpus Fund<br>Capital Fund|**2025**<br>**£**<br>**£**<br>871,510<br>3,339,136<br>4,210,646<br>(3,799,371)<br> (97,206)<br>314,069<br>3,059,034<br>9,365<br>3,382,468<br>**£**<br>**£**<br>1,818,627<br>18,774<br>675,451<br>26,686<br>261,401<br>625,986<br>1,479,711<br>(27,475)<br>(16,982)<br>1,545,067<br>3,382,468<br>324,659<br>3,057,809<br>3,382,468|**2024**<br>**£**<br>**£**<br>920,524<br>2,639,133<br>3,559,657<br>(3,240,715)<br> (35,639)<br>283,303<br>2,754,818<br>20,913<br>3,059,034<br>£<br>£<br>1,657,252<br>25,517<br>631,342<br>30,975<br>326,729<br>490,665<br>1,479,711<br>(86,459)<br>(16,982)<br>1,376,270<br>3,059,034<br>181,742<br>2,877,292<br>3,059,034|**2024**<br>**£**<br>**£**<br>920,524<br>2,639,133<br>3,559,657<br>(3,240,715)<br> (35,639)<br>283,303<br>2,754,818<br>20,913<br>3,059,034<br>£<br>£<br>1,657,252<br>25,517<br>631,342<br>30,975<br>326,729<br>490,665<br>1,479,711<br>(86,459)<br>(16,982)<br>1,376,270<br>3,059,034<br>181,742<br>2,877,292<br>3,059,034|
|---|---|---|---|
||||3,559,657<br>(3,240,715)<br> (35,639)|
||||283,303<br>2,754,818<br>20,913|
||||3,059,034|
||||£<br>1,657,252<br>25,517<br> <br> <br> <br>1,376,270|
||1,479,711<br>(27,475)<br>(16,982)|1,479,711<br>(86,459)<br>(16,982)||
|||||
||||3,059,034|
||||181,742<br>2,877,292|
||||3,059,034|



The restricted funds and capital funds figure for 23/24 has been adjusted to reflect the movement on restricted funds during 23/24. The prior year’s accounts showed £140,962 restricted funds and £2,918,072 Capital funds, totalling £3,059,034. The overall total remains unchanged. 

26 



## **Lepra** 

## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** 

## **YEAR ENDED 31 MARCH 2025** 

## **6 ANALYSIS OF INCOME** 

|**Consolidated**<br>**Note**<br>**Donations and legacies**<br>Community<br>Individual giving<br>Legacies<br>Events<br>Trusts & Corporate<br>**Charitable activities**<br>Programme funding<br>Leprosy Review funding<br>**Other**<br>Other income<br>Leprosy Review<br>**Investments**<br>**Total income**|**Unrestricted**<br>**Funds**<br>**£**<br>133,146<br>2,178,770<br>1,034,697<br>29,842<br>277,794<br>3,654,249<br>14,339<br>-<br>14,339<br>32,972<br>2,473<br>35,445<br>118,379<br>3,822,412|**Restricted**<br>**Funds**<br>**£**<br>-<br>-<br>-<br>-<br>76,663<br>76,663<br>1,970,610<br>30,699<br>2,001,309<br>9,361<br>-<br>9,361<br>-<br>2,087,333|**Total**<br>**2025**<br>**£**<br>133,146<br>2,178,770<br>1,034,697<br>29,842<br>354,457<br>3,730,912<br>1,984,949<br>30,699<br>2,015,648<br>42,333<br>2,473<br>44,806<br>118,379<br>5,909,745|**Unrestricted**<br>**Funds**<br>**£**<br>110,959<br>1,969,306<br>889,860<br>16,338<br>41,580<br>3,028,043<br>138,603<br>-<br>138,603<br>20,642<br>1,766<br>22,408<br>76,915<br>3,265,969|**Restricted**<br>**Funds**<br>**£**<br>2,000<br>-<br>-<br>-<br>124,176<br>126,176<br>1,502,114<br>38,465<br>1,540,579<br>-<br>-<br>-<br>-<br>1,666,755|**Total**<br>**2024**<br>**£**<br>112,959<br>1,969,306<br>889,860<br>16,338<br>165,756|
|---|---|---|---|---|---|---|
|||||||3,154,219|
|||||||1,640,717<br>38,465|
|||||||1,679,182|
|||||||20,642<br>1,766|
|||||||22,408|
|||||||76,915|
|||||||4,932,724|



The legacy income accrual reflected in the above figures is based on income outstanding for those estates where we have received approved estate accounts.  The accrual at the 31st of March 2025 was £225,472 (£2,821 at 31st March 2024). 

At the balance sheet date, Lepra had been notified of a number of legacies which have not been recognised as income in the Statement of Financial Activities as they did not meet the charity’s legacy income recognition criteria.  These legacies are considered part of the Charity’s legacy pipeline and are expected to be realised in future periods. The estimated gross value of these legacies is £1,237,636 (2024: £1,345,210). 

27 



## **Lepra** 

## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** 

## **YEAR ENDED 31 MARCH 2025** 

## **ANALYSIS OF INCOME** 

|**Charity**<br>**Note**<br>**Donations and**<br>**legacies**<br>Community<br>Individual giving<br>Legacies<br>Events<br>Trusts & Corporate<br>**Charitable activities**<br>Programme funding<br>Leprosy Review funding<br>**Other**<br>Other income<br>Leprosy Review<br>**Investments**<br>**Total income**|**Unrestricted**<br>**Funds**<br>**£**<br>133,146<br>665,372<br>1,034,697<br>29,842<br>277,794<br>2,140,851<br>-<br>-<br>-<br>32,972<br>2,473<br>35,445<br>38,790<br>2,215,086|**Restricted**<br>**Funds**<br>**£**<br>-<br>-<br>-<br>76,663<br>76,663<br>238,800<br>30,699<br>269,499<br>-<br>-<br>-<br>-<br>346,162|**Total**<br>**2025**<br>**£**<br>133,146<br>665,372<br>1,034,697<br>29,842<br>354,457<br>2,217,514<br>238,800<br>30,699<br>269,499<br>32,972<br>2,473<br>35,445<br>38,790<br>2,561,248|**Unrestricted**<br>**Funds**<br>**£**<br>**Restricted**<br>**Funds**<br>**£**<br>110,959<br>2,000.<br>688,492<br>-<br>889,860<br>-<br>16,338<br>-<br>41,580<br>103,263<br>1,747,229<br>105,263<br>138,602<br>207,693<br>-<br>38,465<br>138,603<br>246,158<br>20,642<br>-<br>1,766<br>-<br>22,408<br>-<br>13,017<br>-<br>1,921,256<br>351,421|**Total**<br>**2024**<br>**£**<br>112,959<br>688,492<br>889,860<br>16,338<br>144,843|
|---|---|---|---|---|---|
|||||1,747,229|1,852,492|
|||||138,602<br>-<br>138,603<br>20,642<br>1,766<br>22,408<br>13,017<br>1,921,256|346,295<br>38,465|
||||||384,760|
||||||20,642<br>1,766|
||||||22,408|
||||||13,017|
||||||2,272,677|



The legacy income accrual reflected in the above figures is based on income outstanding for those estates where we have received approved estate accounts.  The accrual at the 31st of March 2025 was £225,472 (£2,821 at 31st March 2024). 

At the balance sheet date, Lepra had been notified of a number of legacies which have not been recognised as income in the Statement of Financial Activities as they did not meet the charity’s legacy income recognition criteria.  These legacies are considered part of the Charity’s legacy pipeline and are expected to be realised in future periods. The estimated gross value of these legacies is £1,237,636 (2024: £1,345,210). 

28 



**Lepra** 

## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** 

## **YEAR ENDED 31 MARCH 2025** 

## **7 INVESTMENT INCOME** 

## **Consolidated** 

Investment income comprises interest and dividends received in respect of: 

|Investment income comprises interest and dividends received in respect of:||
|---|---|
|Dividends from quoted UK investments<br>Interest on short term deposits|**2025**<br>**2024**<br>**£**<br>**£**<br>6,765<br>938<br>111,614<br>75,977|
||118,379<br>91,451|



## **Charity** 

Investment income comprises interest and dividends received in respect of: 

|Dividends from quoted UK investments<br>Interest on short term deposits|**2025**<br>**2024**<br>**£**<br>**£**<br>6,765<br>938<br>32,025<br>12,079|
|---|---|
||38,790<br>13,017|



29 



**Lepra** 

## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** 

## **YEAR ENDED 31 MARCH 2025** 

## **8      ANALYSIS OF EXPENDITURE** 

|**Consolidated**<br>**a) Activity**<br>Programmes<br>Research<br>Advocacy<br>Education<br>Leprosy<br>Review<br>**Charitable**<br>**Activities**<br>Database<br>Fundraising<br>Events<br>Trust &<br>Corporate<br>**Cost of**<br>**Generating**<br>**Funds**<br>**Total**<br>**Expenditure**|<br>**Direct**<br>**Costs**<br>**Support**<br>**Costs**<br>**Allocation**<br>**of Central**<br>**Costs**<br>**Total 2025**<br>**Direct Costs**<br>**Support**<br>**Costs**<br>**Allocation**<br>**of Central**<br>**Costs**<br>**Total 2024**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>4,515,048<br>231,988<br>61,285<br>4,808,321<br>4,125,161<br>207,857<br>76,261<br>4,409,279<br>9,018<br>13,472<br>2,081<br>24,571<br>9,021<br>13,406<br>2,590<br>25,017<br>86,897<br>18,200<br>13,760<br>118,857<br>71,681<br>18,167<br>17,123<br>106,971<br>70,256<br>45,954<br>12,987<br>129,197<br>65,739<br>40,620<br>16,161<br>122,520<br>27,838<br>15,178<br>4,649<br>47,665<br>48,343<br>12,546<br>5,785<br>66,674|
|---|---|
||4,709,057<br>324,792<br>94,762<br>5,128,611<br>4,319,945<br>292,596<br>117,920<br>4,730,461<br>245,958<br>96,387<br>21,039<br>363,384<br>246,765<br>77,960<br>26,180<br>350,905<br>25,147<br>19,202<br>3,640<br>47,989<br>17,426<br>16,542<br>4,529<br>38,497<br>104,739<br>12,234<br>5,197<br>122,170<br>70,672<br>12,191<br>6,467<br>89,330|
||375,844<br>127,823<br>29,876<br>533,543<br>334,863<br>106,693<br>37,176<br>478,732|
||5,084,901<br>452,615<br>124,638<br>5,662,154<br>4,654,808<br>399,289<br>155,096<br>5,209,193|



30 



## **Lepra** 

## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** 

## **YEAR ENDED 31 MARCH 2025** 

## **Charity** 

|**a) Activity**<br>Programmes<br>Research<br>Advocacy<br>Education<br>Leprosy<br>Review<br>**Charitable**<br>**Activities**<br>Database<br>Fundraising<br>Events<br>Institutions &<br>Trusts<br>Cost of<br>Generating<br>Funds<br>Total<br>Expenditure|**Direct**<br>**Costs**<br>**Support**<br>**Costs**<br>**Allocation**<br>**of Central**<br>**Costs**<br>**Total 2025**<br>**Direct Costs**<br>**Support**<br>**Costs**<br>**Allocation**<br>**of Central**<br>**Costs**<br>**Total 2024**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>1,587,187<br>231,988<br>61,285<br>1,880,460<br>1,804,969<br>207,857<br>76,261<br>2,089,087<br>9,018<br>13,472<br>2,081<br>24,571<br>9,021<br>13,406<br>2,590<br>25,017<br>86,897<br>18,200<br>13,760<br>118,857<br>71,681<br>18,167<br>17,123<br>106,971<br>70,256<br>45,954<br>12,987<br>129,197<br>65,739<br>40,620<br>16,161<br>122,520<br>27,838<br>15,178<br>4,649<br>47,665<br>48,343<br>12,546<br>5,785<br>66,674|
|---|---|
||1,781,196<br>324,792<br>94,762<br>2,200,750<br>1,999,753<br>292,596<br>117,920<br>2,410,269<br>245,958<br>96,387<br>21,039<br>363,384<br>246,765<br>77,960<br>26,180<br>350,905<br>25,147<br>19,202<br>3,640<br>47,989<br>17,426<br>16,542<br>4,529<br>38,497<br>104,739<br>12,234<br>5,197<br>122,170<br>70,672<br>12,191<br>6,467<br>89,330|
||375,844<br>127,823<br>29,876<br>533,543<br>334,863<br>106,693<br>37,176<br>478,732|
||2,157,040<br>452,615<br>124,638<br>2,734,293<br>2,334,616<br>399,289<br>155,096<br>2,889,001|



## **8  b) Analysis of central costs for apportionment** 

|Programmes<br>Research<br>Advocacy<br>Education<br>Leprosy Review<br>**Charitable Activities**<br>Database Fundraising<br>Events<br>Trust & Corporate<br>**Cost of Generating Funds**<br>**Total Expenditure**|**Office Costs**<br>**Depreciation**<br>**Total 2025**<br>**Total 2024**<br>**£**<br>**£**<br>**£**<br>**£**<br>39,525<br>21,760<br>61,285<br>76,261<br>1,494<br>587<br>2,081<br>2,590<br>9,878<br>3,882<br>13,760<br>17,123<br>9,323<br>3,664<br>12,987<br>16,161<br>3,337<br>1,312<br>4,649<br>5,785|
|---|---|
||63,557<br>31,205<br>94,762<br>117,920<br>15,103<br>5,936<br>21,039<br>26,180<br>2,613<br>1,027<br>3,640<br>4,529<br>3,731<br>1,466<br>5,197<br>6,467|
||21,447<br>8,429<br>29,876<br>37,176|
||85,004<br>39,634<br>124,638<br>155,096|



31 



## **Lepra** 

## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** 

## **YEAR ENDED 31 MARCH 2025** 

|**9**<br>**TANGIBLE FIXED ASSETS-**<br>**CONSOLIDATED**<br>**Cost**<br>1 April 2024<br>Additions<br>Disposals<br>Reclassification to<br>investment properties<br>31 March 2025<br>**Depreciation**<br>1 April 2024<br>Charged for year<br>Released on disposal<br>Reclassification to<br>investment properties<br>31 March 2025<br> <br>**Net book values**<br>1 April 2024<br>31 March 2025|**Land and**<br>**Premises**<br>**Overseas**<br>**Freehold Premises**<br>**UK**<br>**Motor**<br>**Vehicles**<br>**Office &**<br>**Photo**<br>**Equipment**<br>**Computer**<br>**Equipment**<br>**Total**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>1,131,188<br>1,196,631<br>720,877<br>1,866,671<br>45,213<br>4,960,580<br>217,145<br>-<br>30,586<br>124,861<br>4,525<br>377,117<br>-<br>-<br>(9,687)<br>(12,751)<br>-<br>(22,438)<br>-<br>(60,072)<br>-<br>-<br>-<br>(60,072)|
|---|---|
||1,348,333<br>1,136,559<br>741,775<br>1,978,782<br>49,738<br>5,255,187<br>452,433<br>361,688<br>403,615<br>1,192,290<br>32,811<br>2,442,837<br>53,062<br>19,944<br>39,846<br>119,197<br>5,061<br>237,110<br>-<br>-<br>(9,670)<br>(11,989)<br>-<br>(21,659)<br>-<br>(21,788)<br>-<br>-<br>-<br>(21,788)|
||505,495<br>359,844<br>433,791<br>1,299,502<br>37,872<br>2,636,504<br>678,755<br>834,943<br>317,262<br>674,381<br>12,402<br>2,517,743|
||842,838<br>776,715<br>307,983<br>679,280<br>11,866<br>2,618,683|



32 



## **Lepra** 

## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** 

## **YEAR ENDED 31 MARCH 2025** 

|**TANGIBLE FIXED ASSETS**<br>**- CHARITY**<br>**Cost**<br>1 April 2024<br>Additions<br>Disposal<br>Reclassification to<br>investment properties<br>31 March 2025<br>**Depreciation**<br>1 April 2024<br>Charged for year<br>Released on disposal<br>Reclassification to<br>investment properties<br>31 March 2025<br>**Net book values**<br>1 April 2024<br>31 March 2025|**Freehold**<br>**Premises**<br>**UK**<br>**Motor**<br>**Vehicles**<br>**Office &**<br>**Photo Equip**<br>**Computer**<br>**Equipment**<br>**Total**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>1,196,631<br>95,154<br>69,242<br>45,213<br>1,406,240<br>-<br>1,551<br>2,942<br>4,525<br>9,017<br>-<br>(8,977)<br>(2,321)<br>-<br>(11,298)<br>(60,072)<br>-<br>-<br>-<br>(60,072)|
|---|---|
||1,136,559<br>87,727<br>69,863<br>49,738<br>1,343,887<br>361,688<br>93,422<br>57,769<br>32,811<br>545,690<br>19,944<br>1,624<br>4772<br>5,061<br>22,234<br>-<br>(9,164)<br>(2,369)<br>-<br>(11,533)<br>(21,788)<br>-<br>-<br>-<br>(21,788)|
||359,844<br>85,883<br>60,172<br>37,872<br>543,771<br>834,943<br>1,732<br>11,473<br>12,402<br>860,550|
||776,715<br>1,845<br>9,691<br>11,866<br>800,116|



33 



**Lepra** 

## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** 

## **YEAR ENDED 31 MARCH 2025** 

## **10 INVESTMENT PROPERTY ASSETS – Charity and Consolidated** 

|**INVESTMENT PROPERTY ASSETS – Charity and Consolidated**||
|---|---|
|**Valuation**<br>1 April 2024<br>Reclassification from Tangible Fixed Assets<br>Revaluation<br>**31 March 2025**|**Consolidated**<br>**2025**<br>**Total**<br>**Charity**<br>**2025**<br>**Total**<br>**£**<br>**£**<br>283,770<br>283,770<br>38,283<br>38,283<br>(46,558)<br>(46,558)|
||275,495<br>275,495|



As at 31 March 2025, group investment properties were held at the amount £275,495. The revaluation was performed By Fenn Wright in July 25. 

## **11 INTANGIBLE FIXED ASSETS – SOFTWARE** 

|**INTANGIBLE FIXED ASSETS – SOFTWARE**||
|---|---|
|**Cost**<br>1 April 2024<br>Additions<br>Disposals<br>31 March 2025<br>**Amortisation**<br>1 April 2024<br>Charged for year<br>Released on disposal<br>31 March 2025<br>**Net book values**<br>1 April 2024<br>31 March 2025|**Consolidated**<br>**2025**<br>**Consolidated**<br>**2024**<br>**Charity**<br>**2025**<br>**Charity**<br>**2024**<br>**£**<br>**£**<br>**£**<br>**£**<br>121,388<br>119,768<br>119,102<br>117,482<br>768<br>1,620<br>768<br>1,620<br>-<br>-<br>-<br>-|
||122,156<br>121,388<br>119,870<br>119,102<br>111,169<br>91,044<br>108,916<br>88,814<br>8,232<br>20,125<br>8,232<br>20,102<br>-<br>-<br>-<br>-|
||119,401<br>111,169<br>117,148<br>108,916<br>10,219<br>28,724<br>10,186<br>28,668|
||2,755<br>10,219<br>2,722<br>10,186|



34 



## **Lepra** 

## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** 

## **YEAR ENDED 31 MARCH 2025** 

|**12**<br>**FIXED ASSET INVESTMENTS**<br>At Market Value:<br>1 April 2024<br>Add: Additions<br>Less: Disposals in year<br>Net loss on revaluation<br>31 March 2025<br>Historical Cost at the 31 March 2025<br>The Investments are distributed as<br>follows:<br>UK Quoted investments<br>LEPRA India Investments<br>Unquoted Investments<br>31 March 2025|**Consolidated**<br>**Charity**<br>**2025**<br>**2024**<br>**2025**<br>**2024**<br>**£**<br>**£**<br>**£**<br>**£**<br>66,494<br>68,874<br>40,977<br>42,418<br>-<br>-<br>-<br>-<br>6,729<br>-<br>-<br>-<br>(450)<br>(2,380)<br>(450)<br>(1,441)|
|---|---|
||59,315<br>66,494<br>40,527<br>40,977<br>31,976<br>38,719<br>13,202<br>13,202|
||18,299<br>18,735<br>18,299<br>18,735<br>18,774<br>25,517<br>-<br>-<br>22,242<br>22,242<br>22,242<br>22,242|
||59,315<br>66,494<br>40,527<br>40,977|



The unquoted investments are ordinary shares in Helpcards Holdings Ltd of which Lepra holds 6.74% of the issued share capital. 

35 



**Lepra** 

## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** 

## **YEAR ENDED 31 MARCH 2025** 

## **13** 

|**Consolidated**<br>Restricted Funds<br>Designated Funds<br>Unrestricted Funds<br>**Charity**<br>Restricted Funds<br>Designated Funds<br>Unrestricted Funds<br>**Consolidated**<br>Restricted Funds<br>Designated Funds<br>Unrestricted Funds<br>**Charity**<br>Restricted Funds<br>Designated Funds<br>Unrestricted Funds|**2024/2025**<br>**Tangible**<br>**Fixed Assets**<br>**Intangible**<br>**Assets**<br>**Net Current**<br>**Assets**<br>**Investments**<br>**Total**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>-<br>-<br>362,278<br>-<br>362,278<br>-<br>-<br>37,350<br>-<br>37,350<br>2,618,683<br>2,755<br>2,126,810<br>334,810<br>5,083,058|
|---|---|
||2,618,683<br>2,755<br>2,526,438<br>334,810<br>5,482,686|
||**Tangible**<br>**Fixed Assets**<br>**Intangible**<br>**Assets**<br>**Net Current**<br>**Assets**<br>**Investments**<br>**Total**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>-<br>-<br>37,619<br>-<br>37,619<br>-<br>-<br>37,350<br>-<br>37,350<br>800,116<br>2,722<br>906,402<br>316,022<br>2,025,262|
||800,116<br>2,722<br>981,371<br>316,022<br>2,100,231|
||**2023/24**<br>**Tangible**<br>**Intangible**<br>**Assets**<br>**Net Current**<br>**Investments**<br>**Total**<br>**Fixed Assets**<br>**Assets**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>-<br>-<br>205,171<br>-<br>205,171<br>-<br>-<br>491,525<br>-<br>491,525<br>2,517,743<br>10,219<br>1,815,680<br>350,264<br>4,693,906|
||2,517,743<br>10,219<br>2,512,376<br>350,264<br>5,390,602|
||**Tangible**<br>**Intangible**<br>**Assets**<br>**Net Current**<br>**Investments**<br>**Total**<br>**Fixed Assets**<br>**Assets**<br>**£**<br>**£**<br>**£**<br>**£**<br>**£**<br>-<br>-<br>23,429<br>-<br>23,429<br>-<br>-<br>491,526<br>-<br>491,526<br>860,550<br>10,186<br>621,129<br>324,747<br>1,816,612|
||860,550<br>10,186<br>1,136,084<br>324,747<br>2,331,567|



36 



**Lepra** 

## **NOTES TO FINANCIAL STATEMENTS (CONTINUED)** 

## **YEAR END 31 MARCH 2025** 

|**14**<br>**STOCKS**<br>Stock<br>**15**<br>**DEBTORS**<br>Debtors & Prepayments<br>Sundry debtors<br>Amounts owed by group companies<br>Accrued income|**Consolidated**<br>**2025**<br>**2024**<br>**£**<br>**£**<br>26,686<br>30,975<br>26,686<br>30,975<br>**Consolidated**<br>**2025**<br>**2024**<br>**£**<br>**£**<br>364,983<br>425,260<br>4,378<br>3,019<br>-<br>-<br>235,130<br>21,366<br>604,491<br>449,645|**Charity**<br>**2025**<br>**2024**<br>**£**<br>**£**<br>-<br>-|
|---|---|---|
|||-<br>-|
|||**Charity**<br>**2025**<br>**2024**<br>**£**<br>**£**<br>62,096<br>78,426<br>4,378<br>3,019<br>41,486<br>20,083<br>235,130<br>21,366|
|||343,090<br>122,894|



All amounts included above are receivable within one year of the balance sheet date. Some of the amounts within Debtors above are financial instruments measured at present value. 

|**16**<br>**CREDITORS**<br>Due within one year<br>PAYE and other taxes<br>Accruals<br>Trade & Other Creditors<br>Deferred Income|**Consolidated**<br>**2025**<br>**2024**<br>**£**<br>**£**<br>21,645<br>11,411<br>52,082<br>37,489<br>106,972<br>146,215<br>21,804<br>43,608<br>202,503<br>238,723|**Charity**<br>**2025**<br>**2024**<br>**£**<br>**£**<br>21,645<br>11,411<br>52,082<br>37,489<br>62,515<br>42,774<br>21,804<br>43,608|
|---|---|---|
|||158,046<br>135,282|



Some of the amounts within creditors above are financial instruments measured at present value. Included within Other Creditors is an amount of £12,515 (2024: £12,038) relating to outstanding pension liabilities. 

Deferred income includes funding received for projects which commenced on 1 April 2024, analysed as follows: 

|Deferred income brought forward<br>Deferred in the year<br>Released in the year<br>Balance carried forward|**Consolidated**<br>**2025**<br>**2024**<br>**£**<br>**£**<br>43,608<br>20,897<br>21,804<br>43,608<br>(43,608)<br>(20,897)<br>21,804<br>43,608|**Charity**<br>**2025**<br>**2024**<br>**£**<br>**£**<br>43,608<br>20,897<br>21,804<br>43,608<br>(43,608)<br>(20,897)|
|---|---|---|
|||21,804<br>43,608|



37 



## **Lepra** 

## **NOTES TO FINANCIAL STATEMENTS (CONTINUED)** 

## **YEAR END 31 MARCH 2025** 

## **17a OPERATING LEASE INCOME** 

The following operating lease payments are committed to being received over the following period: 

|period:|||||
|---|---|---|---|---|
||**Consolidated**||**Charity**||
||**2025**|**2024**|**2025**|**2024**|
||**£**|**£**|**£**|**£**|
|Leases expiring:|||||
|Within one year|28,808|24,528|28,808|24,528|
|Between two and five years|24,528|24,528|24,528|24,528|
|After five years|-|-|-|-|



During the year income recognised on operating leases was £31,307 in 2025 (£24,528 in 2024). 

38 



## L **epra** 

## **NOTES TO FINANCIAL STATEMENTS (CONTINUED)** 

## **YEAR END 31 MARCH 2025** 

|**18**<br>**UNRESTRICTED FUNDS**<br>**Consolidated**<br>1 April<br>Surplus /(Deficit) for the year<br>Realisation of investment revaluation gains (See note 2d)<br>Transfers between funds<br>(Loss)/ Gain on foreign currency transactions<br>Tax Provision Release BD<br>Corpus Fund<br>31 March<br>**Charity**<br>1 April<br>Surplus /(Deficit) for the year<br>Realisation of investment revaluation gains (See note 2d)<br>Transfers between funds<br>(Loss)/Gain on foreign currency transactions<br>31 March<br>**19**<br>**RESTRICTED FUNDS**<br>**LEPRA India**<br>1 April 2024<br>Incoming Resources<br>Resources Expended<br>31 March 2025<br>**Charity Restricted Funds**<br>1 April 2024<br>Incoming Resources<br>Resources Expended<br>Transfers between funds<br>31 March 2025<br>**Consolidated Total restricted funds**|**2025**<br>**£**<br>4,693,906<br>144,659<br>(47,008)<br>400,000<br>(108,499)<br>-<br>-<br>5,083,058<br>1,816,613<br>(133,060)<br>(47,008)<br>400,000<br>(11,283)<br>2,025,262<br>**2025**<br>**£**<br>181,742<br>1,741,171<br>1,922,913<br>(1,598,254)<br>324,659<br>23,429<br>346,162<br>369,591<br>(331,972)<br>-<br>37,619<br>362,278|**2024**<br>**£**<br>4,984,386<br>(235,089)<br>14,797<br>-<br>(70,188)<br>-<br>-|
|---|---|---|
|||4,693,906|
|||2,370,530<br>(534,164)<br>14,797<br>-<br>(34,550)|
|||1,816,613|
|||**2024**<br>**£**<br>140,962<br>1,315,334|
|||1,456,296<br>(1,274,554)|
|||181,742<br>46,566<br>351,421|
|||397,987<br>(374,558)<br>-|
|||23,429|
|||205,171|



39 



## **Lepra** 

## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** 

## **YEAR ENDED 31 MARCH 2025** 

|**NOTE 19 RESTRICTED FUNDS**<br>**(Continued)**<br>**India**<br>Lepra Society of India<br>**Charity**<br>ILEP India<br>ILEP Bangladesh<br>ILEP Leprosy Review<br>The Datum Foundation<br>St Lazarus Charitable Trust<br>The Anne,Ciara and Niamh Copeland<br>200 Club Trust Fund<br>The Hodge Foundation<br>The Belpech Trust<br>Dorfred Charitable Trust<br>Clark Charitable Trust<br>Souter Charitable Trust<br>The Chalk Cliff Trust<br>N Smith Charitable Trust<br>Pavers<br>**Total Charity**<br>**Total consolidated**|**Balance 1**<br>**April 2023**<br>**£**<br>181,742<br>**181,742**<br>-<br>-<br>-<br>-<br>22,697<br>-<br>-<br>732<br>-<br>-<br>-<br>-<br>**23,429**<br>**205,171**|**Incoming**<br>**Resources**<br>**£**<br>1,741,171<br>**1,741,171**<br>87,099<br>151,701<br>30,699<br>4,000<br>30,263<br>7,400<br>13,500<br>-<br>1,000<br>1,500<br>5,000<br>3,000<br>1,000<br>10,000<br>**346,162**<br>**2,087,333**|**Expenditure**<br>**Adjustment**<br>**£**<br>**£**<br>(1,598,254)<br>-<br>**(1,598,254)**<br>**-**<br>(87,099)<br>-<br>(150,400)<br>-<br>(30,699)<br>-<br>(4,000)<br>-<br>(20,466)<br>-<br>(7,400)<br>-<br>(9,676)<br>-<br>-<br>(732)<br>(1,000)<br>-<br>(1,500)<br>-<br>(5,000)<br>-<br>(3,000)<br>-<br>(1,000)<br>-<br>(10,000)<br>-<br>**(331,240)**<br>**(732)**<br>**(1,929,494)**<br>**(732)**|**Balance**<br>**31**<br>**March**<br>**2024**<br>**£**<br>324,659<br>**324**,**659**<br>-<br>1,301<br>-<br>-<br>32,494<br>-<br>3,824<br>-<br>-<br>-<br>-<br>-<br>-<br>-|
|---|---|---|---|---|
|||||**37,619**|
|||||**362,278**|



40 



## **Lepra** 

## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** 

**YEAR ENDED 31 MARCH 2025** 

## **NOTE 19 RESTRICTED FUNDS (Continued)** 

**Lepra Society India -** This includes funds raised in India from a variety of sources for work on specific projects. 

**Poverty reduction through strengthened health systems in Bangladesh -** HSS Project - TLM Canada (effect:hope). 

**ILEP Projects in India-** funding provided by members of the International Federation of Anti-Leprosy Association (ILEP) for projects in India. 

**ILEP Projects in Bangladesh-** funding provided by members of the International Federation of Anti-Leprosy Association (ILEP) for projects in Bangladesh 

**ILEP Leprosy Review-** funding provided by members of the International Federation of Anti-Leprosy Association (ILEP) for production of Leprosy Review 

**Sonepur RC Refurbishment** - The Datum Foundation 

**Samarth project in Chhattarpur District, Madhya Pradesh State, India** - St Lazarus Charitabel Trust and effect:hope 

**Koraput Referral Unit, Odisha-** The Anne, Ciara and Niamh Copeland 200 Club Trust Fund **,** Dorfed Charitable Trust, Clark Charitable Trust, The Chalk Cliff Trust, N Smith Charitable Trust 

**Bihar Mobile Footwear and Education Van –** The Hodge Foundation 

**Andrah Pradesh Referral Unit -** Souter Charitable Trust 

**Andra Pradesh Footwear and Education Van** - Pavers 

**Upgrading the Footwear Manufacturing Unit, Bihar –** The Belpech Trust 

41 



## **Lepra** 

## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** 

## **YEAR ENDED 31 MARCH 2025** 

|**NOTE 19 RESTRICTED FUNDS**<br>**(Continued)**<br>**Year End 31 March 2024**<br>**India**<br>Lepra Society of India<br>**Charity**<br>ILEP India<br>ILEP Bangladesh<br>ILEP Leprosy Review<br>The Datum Foundation<br>St Lazarus Charitable Trust<br>The Anne,Ciara and Niamh Copeland<br>200 Club Trust Fund<br>Robert Luff<br>The Hodge Foundation<br>The Grace Trust<br>The Belpech Trust<br>S Temple Charitable Trust<br>Evan Cornish<br>**Total Charity**<br>**Total consolidated**|**Balance 1**<br>**April 2023**<br>**£**<br>140,962<br>**140,962**<br>16,375<br>20,664<br>3,002<br>-<br>-<br>-<br>1,929<br>-<br>-<br>-<br>-<br>4,596<br>**46,566**<br>**187,528**|**Incoming**<br>**Resources**<br>**£**<br>1,315,334<br>**1,315,334**<br>134,032<br>75,661<br>38,465<br>6,000<br>30,263<br>5,000<br>15,000<br>5,000<br>2,000<br>25,000<br>15,000<br>-<br>**351,421**<br>**1,666,755**|**Expenditure**<br>**Transfers**<br>**£**<br>**£**<br>(1,274,553)<br>-<br>**(1,274,553)**<br>**-**<br>(150,407)<br>-<br>(96,325)<br>-<br>(41,467)<br>-<br>(6,000)<br>-<br>(7,566)<br>-<br>(5,000)<br>-<br>(16,929)<br>-<br>(5,000)<br>-<br>(2,000)<br>-<br>(24,268)<br>-<br>(15,000)<br>-<br>(4,596)<br>-<br>**(374,558)**<br>**-**<br>**(1,649,112)**<br>**-**|**Balance**<br>**31**<br>**March**<br>**2024**<br>**£**<br>181,742<br>**181,742**<br>-<br>-<br>-<br>-<br>22,697<br>-<br>-<br>-<br>-<br>732<br>-<br>-|
|---|---|---|---|---|
|||||**23,429**|
|||||**205,171**|



42 



**Lepra** 

## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** 

## **YEAR ENDED 31 MARCH 2025** 

|**20**<br>**DESIGNATED FUNDS- CONSOLIDATED**<br>Aspire Project<br>Joint Strategic Plan<br>**DESIGNATED FUNDS- CHARITY**<br>Aspire Project<br>Joint Strategic Plan<br>**DESIGNATED FUNDS- CONSOLIDATED**<br>Aspire Project<br>Joint Strategic Plan<br>**DESIGNATED FUNDS- CHARITY**<br>Aspire Project<br>Joint Strategic Plan|**Balance**<br>**1 April 2024**<br>**£**<br>91,525<br>400,000<br>491,525<br>**Balance**<br>**1 April 2024**<br>**£**<br>91,525<br>400,000<br>491,525<br>**Balance**<br>**1 April 2023**<br>**£**<br>150,548<br>400,000<br>550,548<br>**Balance**<br>**1 April 2023**<br>**£**<br>150,548<br>400,000<br>550,548|**Incoming**<br>**Resources**<br>**£**<br>-<br>-<br>-<br>**Incoming**<br>**Resources**<br>**£**<br>-<br>-<br>-<br>**Incoming**<br>**Resources**<br>**£**<br>-<br>-<br>-<br>**Incoming**<br>**Resources**<br>**£**<br>-<br>-<br>-|**Expenditure**<br>**£**<br>(54,175)<br>(400,000)<br>(454,175)<br>**Expenditure**<br>**£**<br>(54,175)<br>(400,000)<br>(454,175)<br>**Expenditure**<br>**£**<br>(59,023)<br>-<br>(59,023)<br>**Expenditure**<br>**£**<br>(59,023)<br>-<br>(59,023)|**Balance**<br>**31 March**<br>**2025**<br>**£**<br>37,350<br>-|
|---|---|---|---|---|
|||||37,350|
|||||**Balance**<br>**31 March**<br>**2025**<br>**£**<br>37,350<br>-|
|||||37,350|
|||||**Balance**<br>**31 March**<br>**2024**<br>**£**<br>91,525<br>400,000|
|||||491,525|
|||||**Balance**<br>**31 March**<br>**2024**<br>**£**<br>91,525<br>400,000|
|||||491,525|



**Aspire Project -** Integrating skin NTDs into the diagnosis and management of prevalent skin diseases. A 5-year (2021-2026) collaboration project with effect hope. The funds will be spent over the lifetime of the project. Please refer to Trustee report for further information. 

**Joint Strategic Plan (JSP)-** Lepra's Board have designated UK funds in order to complete the JSP - Lepra has been working internationally across the leprosy spectrum from transmission, through disability prevention and medical rehabilitation (DPMR) and advocacy for the duration of the JSP (2021-2024). The designation was to cover the additional costs of implementing the plan compared to the recurrent expenditure inherent in programme delivery. A significant deficit budget has been set for 2023-24, and the level of designated funds was reviewed in 2024/25, and it was agreed by the board that the £400,000 could be released in 24/25. 

43 



## **Lepra** 

## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** 

## **YEAR ENDED 31 MARCH 2025** 

|**21**<br>**ANALYSIS OF CHANGES IN NET DEBT**<br>Cash in hand and at bank at 1 April<br>Balance at 31 March<br>**ANALYSIS OF CHANGES IN NET DEBT**<br>Cash in hand and at bank at 1 April<br>Balance at 31 March<br>**22**<br>**ANALYSIS OF THE BALANCES OF CASH AND CASH**<br>**EQUIVALENTS**<br>Deposits with banks<br>Cash<br>**ANALYSIS OF THE BALANCES OF CASH AND CASH**<br>**EQUIVALENTS**<br>Deposits with banks<br>Cash|**CONSOLIDATED**<br>**1 April 2024**<br>**Non-Cash**<br>**Changes**<br>**Cashflow**<br>**31 March**<br>**2025**<br>**£**<br>**£**<br>**£**<br>**£**<br>1,639,137<br>-<br>(216,824)<br>1,422,313<br>1,639,137<br>-<br>(216,824)<br>1,422,313<br>**CHARITY**<br>**1 April 2024**<br>**Non-Cash**<br>**Changes**<br>**Cashflow**<br>**31 March**<br>**2025**<br>**£**<br>**£**<br>**£**<br>**£**<br>1,142,472<br>-<br>(352,145)<br>796,327<br>1,142,472<br>-<br>(352,145)<br>796,327<br>**Consolidated**<br>**1 April 2024**<br>**Movement**<br>**31 March 2025**<br>**£**<br>**£**<br>**£**<br>1,639,113<br>(216,824)<br>1,422,289<br>24<br>-<br>24<br>1,639,137<br>(216,824)<br>1,422,313<br>**Charity**<br>**1 April 2024**<br>**Movement**<br>**31 March 2025**<br>£<br>£<br>£<br>1,148,448<br>(352,145)<br>796,303<br>24<br>-<br>24<br>1,148,472<br>(352,145)<br>796,327|
|---|---|



44 



**Lepra** 

**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** 

## **YEAR ENDED 31 MARCH 2025** 

## **23       EMPLOYEES** 

|**The head count of employees during the year was as follows:**<br>**2025**<br>Head Office<br>24<br>Overseas<br>431<br>455<br>**The full-time equivalent head count of employee during the year was as follows:**<br>**2025**<br>Head Office<br>20<br>Overseas<br>431<br>451<br>The above excludes volunteers who provide their services free of charge.<br>**Staff costs in respect of employees during the year include:**<br>**Consolidated**<br>**2025**<br>£<br>Wages and salaries<br>2,241,547<br>Social security costs<br>78,002<br>Pension costs<br>61,510<br>Other staff costs<br>11,523<br>2,392,582<br>**Staff costs in respect of employees include:**<br>**Charity**<br>**2025**<br>£<br>Wages and salaries<br>966,720<br>Social Security<br>78,002<br>Pensions costs<br>61,510<br>Other staff costs<br>11,523<br>1,117,755|**2024**<br>21<br>418|
|---|---|
||437|
||**2024**<br>18<br>418|
||434|
||**2024**<br>£<br>1,949,168<br>63,046<br>62,337<br>9,148|
||2,083,699|
||**2024**<br>£<br>936,998<br>63,046<br>62,337<br>9,148|
||1,071,529|



45 



## **Lepra** 

|**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**|||
|---|---|---|
||**2025**|**2024**|
|**YEAR ENDED 31 MARCH 2025**|||
|**23EMPLOYEES (Continued)**|||



## **The number of employees who received total emoluments in the following ranges was:** 

|£60K to £69K|2|1|
|---|---|---|
|£70K to £79K|-|-|
|£80K-£89K|-|-|
|£90-99K|1|1|



The pension payments made to these higher paid employees amounted to £18,246 (£11,597 in 2024). 

The key management personnel of Lepra comprise the Trustees, Chief Executive, Director of Fundraising and Communications, Director of Resources and Director of Programmes & Advocacy in the UK, the Country Director, Head of Programmes, Head of Finance and Head of HR in Bangladesh and the Chief Executive Officer, Head of Finance and Head of Programmes in India. The employee remuneration of key management personnel for Lepra was £507,420 (2024: £445,694), which includes £0 for compensation for loss of office (2024: £0). The Trustees received no remuneration for their services to the Organisation during the period (2024 £nil). During the period two (2024: 1) Trustees incurred expenses of £101 for expenses (2024: £57). 

During 2025 there were redundancy payments of £0 (2024: £0). 

## **24 PENSION COMMITMENTS** 

LEPRA provides pension benefits for staff by making contributions to a Group Personal Pension Plan. The employee is required to pay a minimum of 3% of their gross salary with the charity contributing 5-8% depending upon individual employment contracts.  The scheme complies with Auto Enrolment legislation. As at 31 March 2025 there were 22 staff (25 staff- 2024) who were members of this scheme. The cost of contributions are calculated annually and charged to the income and expenditure account as they arise. The costs for 2025 were £61,510 (2024: £62,337). 

46 



**Lepra** 

## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** 

## **YEAR ENDED 31 MARCH 2025** 

## **25 COST OF AUDIT AND OTHER FINANCIAL SERVICES** 

|Amounts payable in respect of audit and other financial services were:<br>Auditors remuneration in respect of current year<br>Auditors remuneration in respect of prior year<br>Auditors remuneration in respect of non-audit services<br>Overseas Audit fees for separate audit firm<br>**26**<br>**RELATED PARTIES**<br>Transactions with Lepra Society in India:<br>Amounts paid to Lepra Society<br>People's Lepra Foundation<br>Year end debtor balance|**2025**<br>**£**<br>32,436<br>11,400<br>1,800<br>14,284<br>54,713<br>**2025**<br>£<br>871,510<br>887<br>41,486|**2024**<br>**£**<br>26,520<br>13,200<br>1,188<br>8,308|
|---|---|---|
|||47,416|
|||**2024**<br>£<br>920,524<br>932<br>20,083|



People's Lepra Foundation is a incorporated company that is a independent not for profit set up by Lepra Society in 2021 to generate resources for support of organisations supporting people affected by Leprosy and Lymphatic Filariasis. Lepra society have a 98% holding in the company and there are 2 independent Directors as dictated by Indian law. 

Pine Ville Consulting is a consultancy firm operated by Nick Avery, Lepra’s former Director of Resources. Mr Avery provided consultancy services to Lepra between June 2024 and July 2025. His work included advising on a legacy bequeathed to Lepra, for which he was the named executor, and assisting with the preparation and marketing of the Colchester property for sale. The payment of £2,724 in the financial year 2024/25 reflects fees for these professional services. 

47